References
- 1. Exner JH, Dahod S, Pochi PE. Pyogenic granuloma-like acne lesions during isotretinoin therapy. Arch Dermatol 1983;119:808-11.10.1001/archderm.1983.01650340018012
- 2. Campbell JP, Grekin RC, Ellis CN, Matsuda-John SS, Swanson NA, Voorhees JJ. Retinoid therapy is associated with excess granulation tissue responses. J Am Acad Dermatol 1983;9:708-13.10.1016/S0190-9622(83)70184-2
- 3. Bigby M, Stern RS. Adverse reactions to isotretinoin. A report from the Adverse Drug Reaction Reporting System. J Am Acad Dermatol 1988;18:543-52.10.1016/S0190-9622(88)70078-X
- 4. Piraccini BM, Bellavista S, Misciali C, Tosti A, de Berker D, Richert B. Periungual and subungual pyogenic granuloma. Br J Dermatol 2010;163:941-53.10.1111/j.1365-2133.2010.09906.x
- 5. Armstrong K, Weinstein M. Pyogenic granulomas during isotretinoin therapy. J Dermatol Case Rep 2011;5:5-7.10.3315/jdcr.2011.1062
- 6. Blumental G. Paronychia and pyogenic granuloma-like lesions with isotretinoin. J Am Acad Dermatol 1984;10:677-8.10.1016/S0190-9622(84)80289-3
- 7. MacKenzie-Wood AR, Wood G. Pyogenic granuloma-like lesions in a patient using topical tretinoin. Australas J Dermatol 1998;39:248-50.10.1111/j.1440-0960.1998.tb01483.x9838723
- 8. Rademaker M. Adverse effects of isotretinoin: A retrospective review of 1743 patients started on isotretinoin. Australas J Dermatol 2010;51:248-53.10.1111/j.1440-0960.2010.00657.x21198520
- 9. Gutzmer R, Wollenberg A, Ugurel S, Homey B, Ganser A, Kapp A. Cutaneous side effects of new antitumor drugs. Clinical features and management. Dtsch Arztebl Int 2012;109(8):133–40.
- 10. Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol 2015;72:203-18.10.1016/j.jaad.2014.07.03225592338
- 11. Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol 2015;72:221-36.10.1016/j.jaad.2014.07.03325592339
- 12. Chang GC, Yang TY, Chen KC, Yin MC, Wang RC, Lin YC. Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22:4646-8.10.1200/JCO.2004.02.16815542815
- 13. Schad K, Baumann Conzett K, Zipser MC, Enderlin V, Kamarashev J, French LE, et al. Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clin Cancer Res 2010;16:1058–64.10.1158/1078-0432.CCR-09-176620103661
- 14. Nelson AM, Zhao W, Gilliland KL, Zaenglein AL, Liu W, Thiboutot DM. Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol 2009;1:177-87.10.4161/derm.1.3.8258283591120436886
- 15. Guruvayoorappan C, Kuttan G. 13 cis-retinoic acid regulates cytokine production and inhibits angiogenesis by disrupting endothelial cell migration and tube formation. J Exp Ther Oncol 2008;7:173-82.
- 16. Hasegawa K, Namekawa SH, Saga Y. MEK/ERK signaling directly and indirectly contributes to the cyclical self-renewal of spermatogonial stem cells. Stem Cells 2013;31:2517-27.10.1002/stem.1486383420023897718